Policy & Regulation
ESSA Pharma Inc completes underwritten public offering of common shares
23 February 2021 -

ESSA Pharma Inc (Nasdaq: EPIX), a clinical-stage pharmaceutical company that says it is focused on developing novel therapies for the treatment of prostate cancer, announced on Monday that it has completed an underwritten public offering of 4,830,918 of its common shares.

The shares are priced at USD27 per share before underwriting discounts. The company granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The total proceeds from the offering were around USD130m. The joint book-running managers for the offering are Jefferies and Piper Sandler, while lead manager for the offering is Oppenheimer & Co and Bloom Burton Securities Inc acted as co-manager for the offering.

The company aims to use the net proceeds from the offering to fund clinical activities, chemistry, manufacturing and controls, and research and development, working capital and general corporate purposes.



Related Headlines